August 8, 2013
The Japanese Society of Hypertension (JSH) said on August 7 that it has decided to establish an ethics committee within the society amid the scandal surrounding clinical trials on Diovan (valsartan), Novartis Pharma’s blockbuster antihypertensive. The decision was made at...read more